Novo Nordisk H1 2025: Semaglutide Unseats Keytruda from Top with USD 16.7b in Sales On 6 August, Novo Nordisk announced its H1 2025 results, with total revenue of DKK 154.9 billion (USD 22.9 billion) in the 6-month period, up 18% year-on-year (YoY) at constant exchange rates (CER)
However, factors like stress, pollution, aging, and poor diet can reduce its levels
Daily movement drops: nausea or schedule changes can reduce steps and NEAT, shrinking your calorie burn (IAPAM overview)
Ozempic users risk blindness! sounds shocking enough to make people click, share, and panic but the reality is a lot less dramatic
What a Baseline Often Includes your health history, including gallbladder issues, pancreas history, kidney concerns, and thyroid history a current medication list, including supplements weight trend over the last several months blood pressure and heart rate basic symptom review, especially reflux, constipation, and hydration habits Also, a baseline visit often includes realistic goal setting